FDA aims to harmonize its human subject protection regulations with Common Rule
FDA aims to foster gene therapy developments with six new draft guidance documents
FDA Shows that it Means Business in Stopping Stem Cell Clinics that Put Patients at Risk
FDA Shows that it Means Business in Stopping Stem Cell Clinics that Put Patients at Risk
FDA Shows that it Means Business in Stopping Stem Cell Clinics that Put Patients at Risk
FDA Weighs In on When Pregnant Patients Should be Included in Clinical Trials
Passage of Federal Right-to-Try law poses risks and opportunities for patients and the biopharmaceutical industry
FDA Issues Draft Guidance on Requirements for Public Warnings for Recalled Products
The Crackdown Continues: FDA Takes Action Against Company And Its Autologous Stem Cell Product, Alleging Significant Safety Concerns
Blogs
Firm/Org